Author:
Foran James M.,Pavletic Steven Z.,Logan Brent R.,Agovi-Johnson Manza A.,Pérez Waleska S.,Bolwell Brian J.,Bornhäuser Martin,Bredeson Christopher N.,Cairo Mitchell S.,Camitta Bruce M.,Copelan Edward A.,Dehn Jason,Gale Robert P.,George Biju,Gupta Vikas,Hale Gregory A.,Lazarus Hillard M.,Litzow Mark R.,Maharaj Dipnarine,Marks David I.,Martino Rodrigo,Maziarz Richard T.,Rowe Jacob M.,Rowlings Philip A.,Savani Bipin N.,Savoie Mary Lynn,Szer Jeffrey,Waller Edmund K.,Wiernik Peter H.,Weisdorf Daniel J.
Funder
National Cancer Institute, the National Heart, Lung and Blood Institute
National Cancer Institute and the National Heart, Lung and Blood Institute
Office of Naval Research
Allos, Amgen, Angioblast
Medical College of Wisconsin, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Buchanan Family Foundation, CaridianBCT, Celgene, CellGenix, Children’s Leukemia Research Association, Fresenius-Biotech North America, Gamida Cell Teva Joint Venture, Genentech, Genzyme, GlaxoSmithKline, HistoGenetics, Kiadis Pharma, Leukemia and Lymphoma Society, Medical College of Wisconsin, Merck & Co, Millennium: Takeda Oncology, Milliman USA
Miltenyi Biotec, National Marrow Donor Program, Optum Healthcare Solutions, Osiris Therapeutics, Otsuka America Pharmaceutical, RemedyMD, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, StemCyte, Stemsoft Software, Swedish Orphan Biovitrum, Tarix Pharmaceuticals, Teva Neuroscience, Therakos, and Wellpoint
Subject
Transplantation,Hematology